

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6600)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON THURSDAY, MAY 19, 2022

At the annual general meeting (the “AGM”) of SciClone Pharmaceuticals (Holdings) Limited (the “Company”) held on Thursday, May 19, 2022, all the proposed resolutions as set out in the notice of the AGM dated April 14, 2022 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements and the reports of the directors and auditors for the year ended December 31, 2021.	472,087,050 (100%)	0 (0%)
2.	To declare a final dividend of HKD0.35 per ordinary share for the year ended December 31, 2021.	472,087,050 (100%)	0 (0%)
3(a).	To re-elect Mr. Zhao Hong as an executive director of the Company.	472,087,050 (100%)	0 (0%)
3(b).	To re-elect Ms. Lin Shirley Yi-Hsien as a non-executive director of the Company.	472,087,050 (100%)	0 (0%)
3(c).	To re-elect Ms. Li Quan as a non-executive director of the Company.	472,072,550 (99.99%)	14,500 (0.01%)
3(d).	To re-elect Dr. Chen Ping as an independent non-executive director of the Company.	472,072,550 (100%)	0 (0%)
3(e).	To authorize the board of directors to fix the respective directors’ remuneration.	472,087,050 (100%)	0 (0%)
4.	To re-appoint PricewaterhouseCoopers as the auditor and to authorize the board of directors to fix its remuneration.	472,087,050 (100%)	0 (0%)
5.	To give a general mandate to the directors to repurchase shares of the Company not exceeding 10% of total number of issued shares of the Company as at the date of passing of this resolution.	472,087,050 (100%)	0 (0%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
6.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	471,955,570 (99.97%)	131,480 (0.03%)
7.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	471,955,570 (99.97%)	131,480 (0.03%)

Notes:

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 7, all resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the AGM, the total number of shares of the Company in issue was 684,299,263.
- (c) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 683,446,763.
- (d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (e) No shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (f) None of the shareholders of the Company have stated their intention in the Company’s circular dated April 14, 2022 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company’s branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (h) All directors of the Company attended the AGM.

By Order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
*Executive Director, Chief Executive Officer and
President*

Hong Kong, May 19, 2022

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* For identification purpose only